I. COMMENCED TRADING IN SEPTEMBER

Company
(Symbol)

Date
Filed

Date
Comm.

Shares/
Units (M)

Price

Shares
Out (M)

Lead, Other
Underwriters

Gross
(M)

Post-
Offering
Market
Cap (M)

INITIAL OFFERINGS

There were no initial public offerings conducted in September.

Total: $0M

Number of IPOs in September: 0

Average value of September IPOs: $0M

Number of IPOs in 2002: 4

Total raised in IPOs in 2002: $464.7M*

Average value of IPOs in 2002: $116.19M*

* Figures include an overallotment option exercised in January as part of a 2001 IPO.

Figures do not include an IPO conducted in June by YM BioSciences Inc. because the shares were privately placed.

FOLLOW-ON OFFERINGS

Company
(Symbol)#

Date
Filed

Date
Comm.

Shares/
Units (M)

Price

Shares
Out (M)^%

Lead, Other
Underwriters

Gross
(M)

Post-
Offering
Market
Cap (M)^@

Biosante
Pharmaceuticals
Inc. (OTC BB:BISP)¹

5/6/02

9/6

2.25S

$2

8.6

Self-underwritten

$4.5

$17.2

Telik Inc.
(TELK)²

6/3/02

9/27

6.5S

$11.50

34.5

UBS Warburg (lead); Wachovia Securities; Legg Mason Wood Walker; Needham & Company

$74.75

$396.75

Trimeris Inc.
(TRMS)³

8/23/02

9/27

2.4S

$45.25

21.2

Morgan Stanley (co-lead); Goldman Sachs (co-lead); Lehman Brothers; Banc of America Securities

$108.6

$959.3

Total: $187.85M

Number of follow-on offerings in September: 3

Average value of September follow-ons: $62.6M

Number of follow-on offerings in 2002: 18

Total raised in follow-ons in 2002: $717.78M

Average value of follow-ons in 2002: $39.9M

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

% This column reflects the shares outstanding following the offering, when disclosed.

@ Market capitalization calculated is based on the offering price.

OTC = Over-the-Counter Bulletin Board

1. Biosante raised $4.5M in the self-underwritten public offering.

2. Telik's underwriters have an overallotment option for 975,000 shares.

3. Trimeris' underwriters have an overallotment option for 360,000 shares.

II. FILED AND PENDING

Company
(Symbol/
Proposed Symbol)#*

Date
Filed

Shares/
Units (M)

Price
Range

Shares
Out (M)%

Lead, Other
Underwriters

Value (M)

INITIAL OFFERINGS

Corcept Therapeutics
Inc. (CORT)¹

12/21/01

4S

$14-16

23.9

U.S. Bancorp Piper Jaffray (co-lead); CIBC World Markets (co-lead); Thomas Weisel Partners

$60

DiaDexus Inc. (DDXS)²

11/20/00

7S

$12-14

31.1

Lehman Brothers; CIBC World Markets; Robertson Stephens; Fidelity Capital Markets

$91

MitoKor Inc. (MITO)³

3/8/02

N/A

N/A

N/A

RBC Capital Markets; Lazard Freres; Legg Mason Wood Walker; Gerard Klauer Mattison

$60

Novirio Pharmaceuticals
Ltd. (IDIX)⁴

4/12/02

N/A

N/A

N/A

Goldman Sachs (co-lead); Banc of America Securities (co-lead); JP Morgan Securities; U.S. Bancorp Piper Jaffray

$115

Protarga Inc. (PRTG)⁵

12/12/01

N/A

N/A

N/A

UBS Warburg (co-lead); U.S. Bancorp Piper Jaffray (co-lead)

$75

Stem Genetics Inc. (N/A)⁶

7/18/02

1.5S

$7

32.3

Self-underwritten

$10.5

ViaCell Inc. (VIAC)⁷

1/30/02

N/A

N/A

N/A

UBS Warburg; Banc of America Securities; U.S. Bancorp Piper Jaffray

$115

FOLLOW-ON OFFERINGS

Advanced Tissue
Sciences Inc. (ATIS)⁸

6/12/02

10S

$1.07

N/A

N/A

$10.7

Antigenics Inc. (AGEN)⁹

6/13/02

N/A

N/A

33.1

N/A

$100

Aphton Corp. (APHT)¹⁰

7/8/02

5S

$6.50

25.1

N/A

$32.5

Ariad Pharmaceuticals
Inc. (ARIA)¹¹

1/9/02

3S

$5.28

35.4

N/A

$15.84

Biomira Inc. (Canada;
BIOM; TSE:BRA)¹²

5/2/02

N/A

N/A

N/A

N/A

C$150 (US$97.84)

Celgene Corp. (CELG)¹³

12/21/01

N/A

N/A

75.6

N/A

$500

Cell Pathways Inc.
(CLPA)¹⁴

2/7/01

N/A

N/A

N/A

N/A

$25

Cepheid Inc. (CPHD)¹⁵

12/21/01

N/A

N/A

26.56

N/A

$35

Cerus Corp. (CERS)¹⁶

8/13/01

N/A

N/A

15.7

N/A

$300

CollaGenex Pharmaceuticals Inc.
(CGPI)¹⁷

10/26/01

0.965S

$8.01

N/A

Kingsbridge Capital Prentice
Securities

$7.7

Cytogen Corp. (CYTO)¹⁸

10/26/01

10S

$2.50

79.8

N/A

$25

Dyax Corp. (DYAX)¹⁹

4/25/02

5S

$3.66

19.6

N/A

$18.3

EntreMed Inc. (ENMD)²⁰

5/10/02

N/A

N/A

N/A

N/A

$50

Exelixis Inc. (EXEL)²¹

7/30/01

N/A

N/A

49.2

N/A

$150

Genaera Corp. (GENR)²²

11/21/01

N/A

N/A

38.9

N/A

$50

Genaissance Pharmaceuticals Inc.
(GNSC)²³

10/18/01

N/A

N/A

22.8

N/A

$35

Geron Corp. (GERN)²⁴

1/30/02

N/A

N/A

N/A

N/A

$150

Hollis-Eden Pharmaceuticals Inc.
(HEPH)²⁵

2/26/02

3S

$8.71

N/A

N/A

$26.13

InSite Vision Inc.
(AMEX:ISV)²⁶

2/2/01

N/A

N/A

N/A

Ladenburg Thalmann
(placement agent)

$40

Myriad Genetics Inc.
(MYGN)²⁷

11/9/01

N/A

N/A

N/A

N/A

$250

NeoTherapeutics Inc.
(NEOT)²⁸

1/3/01

N/A

N/A

26.9

N/A

$50

Neurogen Corp.
(NRGN)²⁹

8/16/02

N/A

N/A

N/A

N/A

$75

Northwest Biotherapeutics
Inc. (NWBT)³⁰

6/4/02

11S

$3.77

17

C.E. Unterberg, Towbin

$41.5

NPS Pharmaceuticals
Inc. (NPSP)³¹

1/7/02

N/A

N/A

N/A

N/A

$250

Pharmos Corp. (PARS)³²

2/4/02

N/A

N/A

56.6

N/A

$25

SciClone Pharmaceuticals
Inc. (SCLN)³³

11/6/01

N/A

N/A

N/A

N/A

$20

StemCells Inc. (STEM)³⁴

3/8/02

15S

$2.52

25.8

N/A

$37.8

Targeted Genetics Corp.
(TGEN)³⁵

12/13/01

8.84S

$2.57

N/A

N/A

$22.72

Triangle Pharmaceuticals
Inc. (VIRS)³⁶

9/25

N/A

N/A

N/A

N/A

$80

Tularik Inc. (TLRK)³⁷

8/14/01

N/A

N/A

49.2

N/A

$250

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Stock symbols for companies seeking to complete IPOs are proposed.

% This column reflects the shares outstanding following the offering, when disclosed.

N/A = Not available, applicable or reported.

AMEX = American Stock Exchange; TSE = Toronto Stock Exchange

1. Corcept's offering is for 4.5M shares, 4M sold by the company and 500,000 sold by a selling stockholder. The value of Corcept's offering, $60M, is based on the sale of 4M shares at $15 each, the midpoint of the expected price range.

2. DiaDexus' IPO value, $91M, is based on the sale of 7M shares at $13 each, the midpoint of the expected price range. The underwriters have an overallotment option on 1.05M shares.

3. MitoKor filed for an IPO to raise $60M.

4. Novirio filed for an IPO to raise $115M.

5. Protarga filed for an IPO with hopes of raising $75M. It did not disclose the number of shares to be offered or the expected price range.

6. Stem Genetics filed for an IPO to raise $10.5M. It intends to go public on the Over-the-Counter Bulletin Board, but did not specify a proposed symbol in its SEC filing.

7. ViaCell filed for a $115M IPO. No further details were disclosed.

8. Advanced Tissue filed a shelf registration statement with the SEC to issue up to 10M shares of its common stock. The value, $10.7M, is based on the June 12 closing stock price of $1.07.

9. Antigenics filed a shelf registration statement covering the issuance of common and preferred stock, as well as secured and unsecured debt securities, up to $60M. It also had a previous registration with $40M in securities remaining.

10. Aphton filed a shelf registration statement to sell up to 5M shares at a maximum amount of $6.50 per share. The company privately placed 2.5M shares worth $5M in September.

11. Ariad filed a shelf registration statement to sell up to 3M shares. At the Jan. 8 closing stock price, it would raise $15.84M.

12. Biomira filed for a $150M shelf prospectus in Canada.

13. Celgene filed a universal shelf registration statement to offer and sell common stock, debt securities and convertible debt securities, up to a total value of $500M.

14. Cell Pathways filed a shelf registration statement for the sale of $25M in common stock. The company privately placed $4.4M in shares in September.

15. Cepheid filed a shelf registration statement to offer and sell up to $35M of its common stock, preferred stock, debt securities and warrants.

16. Cerus filed to sell up to $300M of common stock and debt in a shelf offering.

17. The value of CollaGenex's proposed offering, $7.7M, is based on the Oct. 26 closing stock price of $8.01. CollaGenex privately placed 119,335 shares in May, raising $1M. It placed 32,187 shares in June, raising $266,667.

18. Cytogen filed to offer 10M shares at about $2.50 each in a shelf registration statement. It privately placed 3M shares in January, and another 4.17M shares in June.

19. Dyax filed a shelf registration statement to sell up to 5M shares. The value, $18.3M, is based on the April 24 closing stock price, $3.66.

20. EntreMed filed a $50M shelf registration statement, allowing it to offer securities from time to time in the form of common stock, preferred stock or warrants to purchase securities.

21. Exelixis filed a shelf registration statement to sell up to $150M in common stock.

22. Genaera filed a universal shelf registration statement for the sale of up to $50M in common stock, preferred stock or warrants to purchase common stock or preferred stock. It privately placed $16.5M in shares in April.

23. Genaissance filed a shelf registration statement to offer and sell common stock, preferred stock, debt or warrants, up to a value of $35M.

24. Geron filed a prospectus for the sale of up to $150M in debt securities, common or preferred stock and warrants.

25. Hollis-Eden filed a shelf registration statement to sell up to 3M shares and warrants from time to time. The value is based on the proposed maximum offering price.

26. InSite filed a shelf registration statement in February 2001 to sell $40M in stock.

27. Myriad filed a shelf registration statement for the sale of up to $250M of various types of securities.

28. NeoTherapeutics filed a shelf registration statement covering the sale of debt securities, common stock, preferred stock, depository shares or warrants up to $50M. In May 2001, the company raised $6M in a private placement. In August, the company privately placed 600,000 shares, raising $2.01M. In November, it placed 950,000 shares, raising $3.8M. In December, it placed 0.77M shares, raising $2.95M. In March 2002, it raised $8.05M in a private placement. In June, it raised $1.66M in a private placement. In July, it raised $1.1M in a private placement.

29. Neurogen filed for a $75M universal shelf registration statement.

30. Northwest expects to offer 11M shares as part of a lock-up agreement with the underwriter from the company's December initial public offering. The value, $41.5M, is based on the June 3 closing stock price of $3.77.

31. NPS filed a shelf registration statement to offer and sell up to $250M of common stock, preferred stock and debt securities.

32. Pharmos filed a shelf registration statement to sell up to $25M of common stock, preferred stock, debt securities and/or warrants.

33. SciClone filed to sell up to $20M in common and preferred stock, debt securities and warrants from time to time through a shelf offering. SciClone privately placed $10.62M in shares in June.

34. StemCells filed with the SEC to sell up to 15M shares to raise a maximum of $37.8M. Further details were not disclosed.

35. Targeted Genetics filed a shelf registration statement for the sale of up to about 8.84M shares of common stock. The value is based on the Jan. 22 closing stock price of $2.57.

36. Triangle filed a shelf registration with the SEC to sell up to $80M in common and preferred stock.

37. Tularik filed to sell up to $250M in common stock and debt securities.